7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile,
lorlatinib,
PF-06463922,
PF06463922,
Lorlatinib,
1454846-35-5,
PF-06463922,
Loratinib,
Lorbrena,
UNII-OSP71S83EU,
Lorlatinib,PF-06463922,
PF 06463922,
OSP71S83EU,
CHEMBL3286830,
PF06463922,
(10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile,
MFCD28144520,
(10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile,
2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-,
lorlantinib,
lorlatinibum,
4cli,
4clj,
Lorbrena (TN),
2H-4,8-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-,
AK175603,
Lorlatinib [USAN:INN],
PFE-PKIS 10,
Lorlatinib (JAN/USAN/INN),
PF06463922(Lorlatinib),
GTPL7476,
Lorlatinib (PF-6463922),
SCHEMBL15261807,
EX-A828,
CHEBI:143117,
(10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-H][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile,
BCP10287,
KS-00000T6C,
2641AH,
BDBM50018830,
s7536,
ZINC98208524,
AKOS027250753,
CS-3983,
DB12130,
SB16884,
NCGC00386417-02,
NCGC00386417-13,
7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile,
BC600707,
HY-12215,
FT-0700455,
PF-6463922,
A14207,
D11012,
J-690185,
(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile,
Rostafuroxin,
Loratinib [USAN],
C21H19FN6O2,
ACN-041467,
B4882,